Jasper Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Current Report on Form 8-K on November 3, 2022, regarding a Nasdaq continued-listing deficiency. The filing does not report quarterly or annual operating results and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
Key Financial and Listing Metrics
- Nasdaq notified the Company that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
- The Company received an initial 180-calendar-day compliance period ending May 2, 2023.
- Compliance requires the common stock to close at or above $1.00 per share for at least 10 consecutive business days before the deadline.
- The notice had no immediate effect on the listing or trading of the common stock or public warrants. The securities remained listed on the Nasdaq Capital Market under JSPR and JSPRW.
- The public warrants are exercisable for common stock at $11.50 per share.
Material Changes, Outlook, and Risks
- If the Company did not regain compliance by May 2, 2023, it might have been eligible for an additional 180-calendar-day compliance period, subject to meeting applicable market-value and other initial listing standards and notifying Nasdaq of its intention to cure the deficiency.
- The Company stated that a reverse stock split could be considered as a potential action to restore compliance.
- If Nasdaq determined that the Company was not eligible or unlikely to cure the deficiency, its securities could become subject to delisting. The Company would have the right to appeal a delisting determination, but there was no assurance that an appeal would succeed.
- The Company intended to monitor its stock price and consider available options, but stated that it could not assure compliance with the minimum bid price requirement or other Nasdaq listing standards.
- The filing’s forward-looking statements are subject to risks and uncertainties, including the Company’s ability to satisfy Nasdaq requirements, obtain any available relief, or maintain continued listing.
Investor Verification Checklist
- Verify whether Jasper regained compliance with Nasdaq’s minimum bid price requirement by May 2, 2023, or received an additional compliance period.
- Check subsequent filings for any reverse stock split, delisting notice, appeal, or change in trading status.
- Review subsequent Forms 10-Q and 10-K for the Company’s cash position, operating losses, financing needs, and going-concern or liquidity disclosures.
- Assess whether the listing deficiency affected the value, liquidity, or exercise economics of the JSPR common stock and JSPRW warrants.